Impact of modified system of objectified judgement analysis (SOJA) methodology on prescribing costs of ACE inhibitors

Clinical Drug Investigation

Volumn 26, Issue 9, 2006, Pages 485-494

  Alabbadi, Ibrahim ^a   Crealey, Grainne ^a   Scott, Michael ^b   Baird, Simon ^c   Trouton, Tom ^b   Mairs, Jill ^b   McElnay, James ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b NORTHERN HEALTH AND SOCIAL CARE TRUST   (United Kingdom)

^c Broughshane Medical Practice   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; IMIDAPRIL; LISINOPRIL; MOEXIPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

BUDGET; CLINICAL TRIAL; DRUG COST; DRUG ELIMINATION; DRUG FORMULARY; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; EVIDENCE BASED MEDICINE; FOOD DRUG INTERACTION; HEALTH SURVEY; HUMAN; IRELAND; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL LITERATURE; PANEL STUDY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL ANALYSIS; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHEMISTRY, PHARMACEUTICAL; DECISION SUPPORT TECHNIQUES; DRUG COSTS; HUMANS; RISK ASSESSMENT;

EID: 33747395384     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626090-00001     Document Type: Review

References (17)

1. Duthie T, Trueman P, Chancellor J, et al. Research into the use of health economics in decision making in the United Kingdom: phase II. Is health economics 'for good or evil'? Health Policy 1999 Jan; 46 (2): 143-57
2. Haas J, Phillips K, Gerstenberger E, et al. Potential savings from substituting generic drugs for brand-name drugs. Ann Intern Med 2005; 142: 891-7
3. Titlow K, Randel L, Clancy CM, et al. Drug coverage decisions: the role of dollars and values. Health Aff 2000 Mar-Apr; 19 (2): 240-7
4. Sheldon TA, Cullum N, Dawson D, et al. What's the evidence that NICE guidance has been implemented? [letter]. BMJ 2004 Oct 30; 329 (7473): 999
5. Karr A. The comparative utilisation of resources evaluation model: a CURE for all diseases. Pharm J 2000; 265 (7119): 619-21
6. Moore AP, Wheeldon NM, Jennings M. A formulary analysis of angiotensin II antagonists in a UK teaching hospital. Dis Manage Health Outcomes 2002; 10 (6): 355-62
7. Janknegt R, Steenhoek A. The System of Objectified Judgement Analysis (SOJA): a tool in rational drug selection for formulary inclusion. Drugs 1997 Apr; 53 (4): 550-62
8. Gerbrandt KR, Yedinak KC. Formulary management of ACE inhibitors. Pharmacoeconomics 1996 Dec; 10 (6): 594-613
9. Verme-Gibboney C. Oral angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm 1997 Dec 1; 54 (23): 2689-703
10. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004; (2): CD004804
11. Chapman RH, Bernner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147-52
12. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998 Apr 14; 97 (14): 1411-20
13. Pilote L, Abrahamowicz M, Rodrigues E. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004 Jul 20; 141 (2): 102-12
14. Fretheim A, Oxman A. International variation in prescribing antihypertensive drugs: its extent and possible explanations. BMC Health Serv Res 2005; 5: 21 (10 pages)
15. Rangoonwala B, Schulz W, Bauer B. Fixed dose combinations of ACE inhibitors. Br J Clin Pract 1996 Dec; 50 (8): 454-65
16. Brown MJ, Cruickshank JK, Dominiczak AF, et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003 Feb; 17 (2): 81-6
17. Jones G. Procuring safer medicines. Hospital Pharmacist 2003; 10: 501-2